An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...

A phase 1 NEJM interim analysis found that a single infusion of the investigational base-editing therapy VERVE-102 produced ...

If it continues to work in further studies, a gene therapy in development could eliminate the need for daily pills or regular ...

LDL cholesterol still drives treatment decisions in assessing heart disease risk, but a new study suggests apolipoprotein B (apoB), which measures artery-clogging particles, could do a better job. In ...

A new daily pill could reduce bad cholesterol levels by 60%, according to a new study. Enlicitide, which was developed by Merck, lowered “bad” LDL cholesterol by more than half in a global study ...

Despite guideline recommendations, evidence from randomized trials evaluating the appropriate low-density lipoprotein (LDL) cholesterol target for secondary prevention in patients with atherosclerotic ...

Incidence of primary end point lower for patients with target LDL level 55 mg/dL versus 70 mg/dL. (HealthDay News) — For patients with atherosclerotic cardiovascular disease (ASCVD), targeting a ...

Target levels of LDL cholesterol keep going down, but should we use higher doses of statins to achieve those goals? Hydroxymethylglutaryl- coenzyme A (HMG-CoA) reductase inhibitors, otherwise known as ...

MADRID, Spain—The European Society of Cardiology and the European Atherosclerosis Society (ESC/EAS) have updated their guidelines for the management of dyslipidemia, and while treatment goals have ...

One of the most common questions I hear from patients is, "My cholesterol was flagged as abnormal, but you told me everything looked good. How can that be?" Recently, a patient named Rose asked ...

Inverse-probability reweighting of NHANES 1988–1991 to 2021–2023 demographics projected 5.3 million US adults with ASCVD and Lp(a) ≥70 mg/dL. Eligible patients were predominantly female (57%), mean ...

For patients with atherosclerotic cardiovascular disease (ASCVD), targeting a low-density lipoprotein (LDL) cholesterol level of <55 mg/dL results in a lower risk for cardiovascular events, according ...